entity

sess_sda-2026-04-01-003

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about sess_sda-2026-04-01-003: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections

0Hypotheses

2Analyses

1Outgoing

0Incoming

0Experiments

2Debates

No AI portrait yet

Outgoing (1)

Target	Relation	Type	Str
processed	causal_extracted	sentinel	0.00

Incoming (0)

Source	Relation	Type	Str
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (2)

Scientific analyses that reference this entity

What brain concentrations of SCFAs are achieved via oral probiotics and are they

pharmacokinetics | 2026-04-11 | 0 hypotheses

Gut-Brain Axis Therapeutics for AD

neurodegeneration | 2026-04-01 | 1 hypotheses Top: 0.525

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (2)

Multi-agent debates referencing this entity

The debate highlighted that while SCFAs can cross the blood-brain barrier, the a

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

Can gut-brain axis modulation prevent or slow Alzheimer's disease pathology?

closed · Rounds: 4 · Score: 0.95 · 2026-04-06

Related Research

Hypotheses and analyses mentioning sess_sda-2026-04-01-003 in their description or question text

No additional research found